Table 1.
Participants’ demographic and clinical characteristics.
| PD-RLS+ (n = 14) | PD-RLS− (n = 20) | NC (n = 19) | P | |
|---|---|---|---|---|
| Gender (M/F) | 5/9 | 12/8 | 7/12 | 0.252 |
| Age (years) | 62.86 ± 2.25 | 64.60 ± 1.29 | 62.84 ± 1.61 | 0.678 |
| MMSE | 28.21 ± 0.47 | 27.90 ± 0.36 | 28.21 ± 0.38 | 0.803 |
| HAMD | 4.21 ± 0.51 | 3.65 ± 0.53 | 3.42 ± 0.48 | 0.576 |
| PD onset age | 57.57 ± 2.68 | 58.60 ± 1.95 | – | 0.753 |
| Levodopa equivalent doses (mg/day) | 296.43 ± 42.08 | 377.50 ± 46.24 | – | 0.226 |
| MDS-UPDRS | 54.14 ± 6.27 | 50.30 ± 4.11 | – | 0.596 |
| UPDRS I | 8.29 ± 1.00 | 7.45 ± 1.23 | – | 0.625 |
| UPDRS II | 12.36 ± 1.72 | 11.35 ± 1.15 | – | 0.615 |
| UPDRS III | 31.14 ± 4.23 | 29.20 ± 2.61 | – | 0.682 |
| UPDRS IV | 2.36 ± 0.96 | 2.30 ± 0.79 | – | 0.963 |
| H&Y stage | 2.11 ± 0.20 | 1.92 ± 0.11 | – | 0.394 |
| PDQ-39 | 31.79 ± 5.23 | 32.80 ± 4.29 | – | 0.881 |
| NMSS | 39.25 ± 5.66 | 40.83 ± 9.89 | – | 0.891 |
| PDSS | 106.50 ± 6.09 | 121.80 ± 4.58 | – | 0.049* |
| IRLS | 14.50 ± 1.70 | 0.00 | – | 0.000* |
HAMD: Hamilton Depressive Rating Scale; H&Y: Hoehn & Yahr scale; IRLS: International Restless Legs Syndrome Study Group Rating Scale; MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; MMSE: Mini Mental State Examination; NC: normal controls; NMSS: Non-Motor Symptoms Scale; PD: Parkinson’s disease; PDQ-39: Parkinson's Disease Questionnaire-39; PD-RLS+: Parkinson’s disease with restless legs syndrome; PD-RLS−: Parkinson’s disease without restless legs syndrome; PDSS: Parkinson’s Disease Sleep Scale.
*P < 0.05.